Please login to the form below

Not currently logged in
Email:
Password:

Servier

This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.

Amgen, Servier heart failure drug clears trial hurdle

Amgen, Servier heart failure drug clears trial hurdle

Amgen and Servier have inched closer to a verdict on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their first phase 3 study passed a futility review. ... than Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's

Latest news

More from news
Approximately 18 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    At this year’s American Society of Haematology (ASH) meeting, Allogene and partner Servier presented phase 1 data for their UCART19 candidate in ALL which revealed impressive response rates.

  • Pharma deals continue to slide Pharma deals continue to slide

    The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.

  • Deal Watch March 2017 Deal Watch March 2017

    name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and

  • Deal Watch January 2017 Deal Watch January 2017

    What goes around, comes around The appetite for immuno-oncology (IO) has survived well into 2017 with Servier closing the biggest IO headline deal in January with Pieris for $1.7bn ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics